Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective

J. S. Bevan, J. Newell-Price, J. A H Wass, Stephen Atkin, P. M. Bouloux, J. Chapman, J. R E Davis, T. A. Howlett, H. S. Randeva, P. M. Stewart, A. Viswanath

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objective: The introduction of ready-to-use lanreotide Autogel® has presented the possibility of patients receiving their acromegaly treatment at home. The objective of this study was to assess the ability of patients (or their partners) to administer repeat, unsupervised, injections of lanreotide Autogel without compromising efficacy or safety. Design: Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study. Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group). Patients received monthly injections of lanreotide Autogel® at their established dose. Effects were monitored for up to 40 weeks. Patients: Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel® (60, 90 or 120 mg) for ≥ 4 months before screening. Measurements: The main outcome measure was the proportion of patients/partners who successfully administered injections throughout the study. Results: All Test group patients/partners qualified to administer injections. Fourteen of 15 patients fulfilled all criteria for successful administration of unsupervised injections (95% confidence interval, 70%-99%). Fourteen of 15 Test and 14/15 Control patients maintained growth hormone and IGF-1 control. Local injection tolerability was good for both treatment groups, and safety profiles were similar. All Test group patients continued with unsupervised injections after the study. Conclusions: Patients with acromegaly or their partners were able to administer lanreotide Autogel® injections with no detrimental effect on efficacy and safety; therefore, unsupervised home injections are a viable alternative to healthcare professional injections for suitably motivated patients.

Original languageEnglish
Pages (from-to)343-349
Number of pages7
JournalClinical Endocrinology
Volume68
Issue number3
DOIs
Publication statusPublished - Mar 2008
Externally publishedYes

Fingerprint

Acromegaly
Injections
Safety
lanreotide
Delivery of Health Care
Insulin-Like Growth Factor I
Growth Hormone
Teaching
Therapeutics

ASJC Scopus subject areas

  • Endocrinology

Cite this

Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective. / Bevan, J. S.; Newell-Price, J.; Wass, J. A H; Atkin, Stephen; Bouloux, P. M.; Chapman, J.; Davis, J. R E; Howlett, T. A.; Randeva, H. S.; Stewart, P. M.; Viswanath, A.

In: Clinical Endocrinology, Vol. 68, No. 3, 03.2008, p. 343-349.

Research output: Contribution to journalArticle

Bevan, JS, Newell-Price, J, Wass, JAH, Atkin, S, Bouloux, PM, Chapman, J, Davis, JRE, Howlett, TA, Randeva, HS, Stewart, PM & Viswanath, A 2008, 'Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective', Clinical Endocrinology, vol. 68, no. 3, pp. 343-349. https://doi.org/10.1111/j.1365-2265.2007.03044.x
Bevan, J. S. ; Newell-Price, J. ; Wass, J. A H ; Atkin, Stephen ; Bouloux, P. M. ; Chapman, J. ; Davis, J. R E ; Howlett, T. A. ; Randeva, H. S. ; Stewart, P. M. ; Viswanath, A. / Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective. In: Clinical Endocrinology. 2008 ; Vol. 68, No. 3. pp. 343-349.
@article{b69292b6503c4a928b5958e3d4b72eff,
title = "Home administration of lanreotide Autogel{\circledR} by patients with acromegaly, or their partners, is safe and effective",
abstract = "Objective: The introduction of ready-to-use lanreotide Autogel{\circledR} has presented the possibility of patients receiving their acromegaly treatment at home. The objective of this study was to assess the ability of patients (or their partners) to administer repeat, unsupervised, injections of lanreotide Autogel without compromising efficacy or safety. Design: Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study. Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group). Patients received monthly injections of lanreotide Autogel{\circledR} at their established dose. Effects were monitored for up to 40 weeks. Patients: Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel{\circledR} (60, 90 or 120 mg) for ≥ 4 months before screening. Measurements: The main outcome measure was the proportion of patients/partners who successfully administered injections throughout the study. Results: All Test group patients/partners qualified to administer injections. Fourteen of 15 patients fulfilled all criteria for successful administration of unsupervised injections (95{\%} confidence interval, 70{\%}-99{\%}). Fourteen of 15 Test and 14/15 Control patients maintained growth hormone and IGF-1 control. Local injection tolerability was good for both treatment groups, and safety profiles were similar. All Test group patients continued with unsupervised injections after the study. Conclusions: Patients with acromegaly or their partners were able to administer lanreotide Autogel{\circledR} injections with no detrimental effect on efficacy and safety; therefore, unsupervised home injections are a viable alternative to healthcare professional injections for suitably motivated patients.",
author = "Bevan, {J. S.} and J. Newell-Price and Wass, {J. A H} and Stephen Atkin and Bouloux, {P. M.} and J. Chapman and Davis, {J. R E} and Howlett, {T. A.} and Randeva, {H. S.} and Stewart, {P. M.} and A. Viswanath",
year = "2008",
month = "3",
doi = "10.1111/j.1365-2265.2007.03044.x",
language = "English",
volume = "68",
pages = "343--349",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective

AU - Bevan, J. S.

AU - Newell-Price, J.

AU - Wass, J. A H

AU - Atkin, Stephen

AU - Bouloux, P. M.

AU - Chapman, J.

AU - Davis, J. R E

AU - Howlett, T. A.

AU - Randeva, H. S.

AU - Stewart, P. M.

AU - Viswanath, A.

PY - 2008/3

Y1 - 2008/3

N2 - Objective: The introduction of ready-to-use lanreotide Autogel® has presented the possibility of patients receiving their acromegaly treatment at home. The objective of this study was to assess the ability of patients (or their partners) to administer repeat, unsupervised, injections of lanreotide Autogel without compromising efficacy or safety. Design: Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study. Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group). Patients received monthly injections of lanreotide Autogel® at their established dose. Effects were monitored for up to 40 weeks. Patients: Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel® (60, 90 or 120 mg) for ≥ 4 months before screening. Measurements: The main outcome measure was the proportion of patients/partners who successfully administered injections throughout the study. Results: All Test group patients/partners qualified to administer injections. Fourteen of 15 patients fulfilled all criteria for successful administration of unsupervised injections (95% confidence interval, 70%-99%). Fourteen of 15 Test and 14/15 Control patients maintained growth hormone and IGF-1 control. Local injection tolerability was good for both treatment groups, and safety profiles were similar. All Test group patients continued with unsupervised injections after the study. Conclusions: Patients with acromegaly or their partners were able to administer lanreotide Autogel® injections with no detrimental effect on efficacy and safety; therefore, unsupervised home injections are a viable alternative to healthcare professional injections for suitably motivated patients.

AB - Objective: The introduction of ready-to-use lanreotide Autogel® has presented the possibility of patients receiving their acromegaly treatment at home. The objective of this study was to assess the ability of patients (or their partners) to administer repeat, unsupervised, injections of lanreotide Autogel without compromising efficacy or safety. Design: Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study. Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group). Patients received monthly injections of lanreotide Autogel® at their established dose. Effects were monitored for up to 40 weeks. Patients: Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel® (60, 90 or 120 mg) for ≥ 4 months before screening. Measurements: The main outcome measure was the proportion of patients/partners who successfully administered injections throughout the study. Results: All Test group patients/partners qualified to administer injections. Fourteen of 15 patients fulfilled all criteria for successful administration of unsupervised injections (95% confidence interval, 70%-99%). Fourteen of 15 Test and 14/15 Control patients maintained growth hormone and IGF-1 control. Local injection tolerability was good for both treatment groups, and safety profiles were similar. All Test group patients continued with unsupervised injections after the study. Conclusions: Patients with acromegaly or their partners were able to administer lanreotide Autogel® injections with no detrimental effect on efficacy and safety; therefore, unsupervised home injections are a viable alternative to healthcare professional injections for suitably motivated patients.

UR - http://www.scopus.com/inward/record.url?scp=39149094648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149094648&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2007.03044.x

DO - 10.1111/j.1365-2265.2007.03044.x

M3 - Article

VL - 68

SP - 343

EP - 349

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -